+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

China Lung Cancer Therapeutics Market Size, Share and Trends Analysis Report by Disease Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), Therapeutic Class (Chemotherapy, Immunotherapy) 2024-2030

  • PDF Icon

    Report

  • 150 Pages
  • September 2024
  • Region: China
  • Grand View Research
  • ID: 6009875
Description Jump to:
The China lung cancer therapeutics market size is anticipated to reach USD 5.34 billion by 2030 and is projected to grow at a CAGR of 13.7% from 2024 to 2030. Increasing incidence of lung cancer, growing awareness and screening initiatives, and adoption of targeted therapies in the country is projected to drive the market growth over the forecast years.

In June 2024, the FLAURA2 clinical trial investigated the efficacy of Tagrisso (osimertinib) in combination with chemotherapy compared to standard care for patients with advanced non-small cell lung cancer (NSCLC), particularly focusing on a cohort of Chinese patients. The results demonstrated that this combination therapy significantly reduced the risk of disease progression or death by nearly 50%. This finding is pivotal as it indicates a substantial improvement in patient outcomes, which is anticipated to influence treatment protocols and market dynamics.

The Chinese government has recognized the growing burden of cancer and has taken significant steps to enhance funding and support for research. Initiatives from organizations such as the National Natural Science Foundation of China (NSFC) and the National Major Scientific and Technological Special Project for “Significant New Drugs Development” are aimed at fostering innovation in drug development. This governmental backing is crucial in driving advancements in therapeutics.

China Lung Cancer Therapeutics Market Report Highlights

  • Based on disease type, the NSCLC segment led the market with the largest revenue share of 84.27% in 2023, driven by the increasing smoking rates
  • Based on therapeutic class, the targeted therapy segment led the market with the largest revenue share of 39.1% in 2023. The growth is attributed to the increasing prevalence of cancer within the population which has created an urgent need for more effective treatment options
  • In December 2023, Simcere Zaiming Pharmaceutical Co., Ltd. announced a significant development regarding COSELA (Trilaciclib Hydrochloride for Injection), an innovative oncology product that is co-developed with G1 Therapeutics. The approval notice from the National Medical Products Administration of China (NMPA) for the Supplementary Application of Drugs marks a pivotal moment for this medication, which is designed to improve outcomes for patients

The leading players in the China Lung Cancer Therapeutics market include:

  • AstraZeneca
  • Roche
  • Pfizer
  • Novartis
  • Merck & Co.
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Boehringer Ingelheim
  • Johnson & Johnson (Janssen Pharmaceuticals)
  • BeiGene
  • Innovent Biologics
  • Jiangsu Hengrui Medicine Co., Ltd.
  • China National Pharmaceutical Group (Sinopharm)
  • Shanghai Junshi Biosciences Co., Ltd.

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Disease type
1.2.2. Therapeutics class
1.2.3. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Disease type outlook
2.2.2. Therapeutics class outlook
2.3. Competitive Insights
Chapter 3. China Lung Cancer Therapeutics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing incidence of lung cancer
3.2.1.2. Aging population
3.2.1.3. Advancements in medical diagnostic equipment
3.2.2. Market Restraint Analysis
3.2.2.1. High costs of advanced immunotherapies and targeted therapies
3.3. China Lung Cancer Therapeutics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
Chapter 4. China Lung Cancer Therapeutics Market: Disease Type Estimates & Trend Analysis
4.1. Disease Type Segment Dashboard
4.2. China Lung Cancer Therapeutics Market: Disease Type Movement Analysis
4.3. China Lung Cancer Therapeutics Market by Disease Type Outlook (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5. Non-small Cell Lung Cancer (NSCLC)
4.5.1. Non-small Cell Lung Cancer (NSCLC) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Small Cell Lung Cancer (SCLC)
4.6.1. Small Cell Lung Cancer (SCLC) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. China Lung Cancer Therapeutics Market: Therapeutics Class Estimates & Trend Analysis
5.1. Therapeutics Class Segment Dashboard
5.2. China Lung Cancer Therapeutics Market: Therapeutics Class Movement Analysis
5.3. China Lung Cancer Therapeutics Market by Therapeutics Class Outlook (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5. Chemotherapy
5.5.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Radiation Therapy
5.6.1. Radiation Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Immunotherapy
5.7.1. Immunotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8. Targeted Therapy
5.8.1. Targeted Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.9. Other Treatments
5.9.1. Other Treatments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Competitive Landscape
6.1. Market Participant Categorization
6.2. Key Company Profiles
6.2.1. AstraZeneca
6.2.1.1. Company overview
6.2.1.2. Financial performance
6.2.1.3. Product benchmarking
6.2.1.4. Strategic initiatives
6.2.2. Roche
6.2.2.1. Company overview
6.2.2.2. Financial performance
6.2.2.3. Product benchmarking
6.2.2.4. Strategic initiatives
6.2.3. Pfizer
6.2.3.1. Company overview
6.2.3.2. Financial performance
6.2.3.3. Product benchmarking
6.2.3.4. Strategic initiatives
6.2.4. Novartis
6.2.4.1. Company overview
6.2.4.2. Financial performance
6.2.4.3. Product benchmarking
6.2.4.4. Strategic initiatives
6.2.5. Merck & Co.
6.2.5.1. Company overview
6.2.5.2. Financial performance
6.2.5.3. Product benchmarking
6.2.5.4. Strategic initiatives
6.2.6. Bristol-Myers Squibb
6.2.6.1. Company overview
6.2.6.2. Financial performance
6.2.6.3. Product benchmarking
6.2.6.4. Strategic initiatives
6.2.7. Eli Lilly and Company
6.2.7.1. Company overview
6.2.7.2. Financial performance
6.2.7.3. Product benchmarking
6.2.7.4. Strategic initiatives
6.2.8. Boehringer Ingelheim
6.2.8.1. Company overview
6.2.8.2. Financial performance
6.2.8.3. Product benchmarking
6.2.8.4. Strategic initiatives
6.2.9. Johnson & Johnson (Janssen Pharmaceuticals)
6.2.9.1. Company overview
6.2.9.2. Financial performance
6.2.9.3. Product benchmarking
6.2.9.4. Strategic initiatives
6.2.10. BeiGene
6.2.10.1. Company overview
6.2.10.2. Financial performance
6.2.10.3. Product benchmarking
6.2.10.4. Strategic initiatives
6.2.11. Innovent Biologics
6.2.11.1. Company overview
6.2.11.2. Financial performance
6.2.11.3. Product benchmarking
6.2.11.4. Strategic initiatives
6.2.12. Jiangsu Hengrui Medicine Co., Ltd.
6.2.12.1. Company overview
6.2.12.2. Financial performance
6.2.12.3. Product benchmarking
6.2.12.4. Strategic initiatives
6.2.13. China National Pharmaceutical Group (Sinopharm)
6.2.13.1. Company overview
6.2.13.2. Financial performance
6.2.13.3. Product benchmarking
6.2.13.4. Strategic initiatives
6.2.14. Shanghai Junshi Biosciences Co., Ltd.
6.2.14.1. Company overview
6.2.14.2. Financial performance
6.2.14.3. Product benchmarking
6.2.14.4. Strategic initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 China lung cancer therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 4 China lung cancer therapeutics market, by therapeutic class, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Information Procurement
Fig. 2 Primary Research Pattern
Fig. 3 Market Research Approaches
Fig. 4 Value Chain-Based Sizing & Forecasting
Fig. 5 Market Formulation & Validation
Fig. 6 China lung cancer therapeutics market segmentation
Fig. 7 Market driver analysis (Current & future impact)
Fig. 8 Market restraint analysis (Current & future impact)
Fig. 9 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 10 Porter’s Five Forces Analysis
Fig. 11 China lung cancer therapeutics market, disease type outlook key takeaways (USD Million)
Fig. 12 China lung cancer therapeutics market: disease type movement analysis 2023 & 2030 (USD Million)
Fig. 13 Non-small cell lung cancer (NSCLC) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 14 Small cell lung cancer (SCLC) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 15 China lung cancer therapeutics market, therapeutic class outlook key takeaways (USD Million)
Fig. 16 China lung cancer therapeutics market: therapeutic class movement analysis 2023 & 2030 (USD Million)
Fig. 17 Chemotherapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 18 Radiation therapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 19 Immunotherapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Targeted therapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Other treatments market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 China lung cancer therapeutics Market, end use outlook key takeaways (USD Million)

Companies Mentioned

The leading players in the China Lung Cancer Therapeutics market include:
  • AstraZeneca
  • Roche
  • Pfizer
  • Novartis
  • Merck & Co.
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Boehringer Ingelheim
  • Johnson & Johnson (Janssen Pharmaceuticals)
  • BeiGene
  • Innovent Biologics
  • Jiangsu Hengrui Medicine Co., Ltd.
  • China National Pharmaceutical Group (Sinopharm)
  • Shanghai Junshi Biosciences Co., Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages150
PublishedSeptember 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 2.18 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.34 Billion
Compound Annual Growth Rate13.7%
Regions CoveredChina
No. of Companies Mentioned15

Related Topics

Related Reports

Lung Cancer Drugs Market by Disease, Molecule, Distribution Channel - Global Forecast 2025-2030 - Product Image

Lung Cancer Drugs Market by Disease, Molecule, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From
Immune Checkpoint Inhibitors for Lung Cancer Market by Products, Type, End-Users - Global Forecast 2025-2030 - Product Image

Immune Checkpoint Inhibitors for Lung Cancer Market by Products, Type, End-Users - Global Forecast 2025-2030

  • Report
  • 183 Pages
  • Global
From
Non-small Cell Lung Cancer Therapeutics Market Size, Share & Trends Analysis Report By Type (Squamous Cell Carcinoma), By Treatment (Chemotherapy), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Non-small Cell Lung Cancer Therapeutics Market Size, Share & Trends Analysis Report By Type (Squamous Cell Carcinoma), By Treatment (Chemotherapy), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 100 Pages
  • Global
From
Non-small Cell Lung Cancer Therapeutics Market by Cancer Type, Drug Class, Distribution Channel - Global Forecast 2025-2030 - Product Image

Non-small Cell Lung Cancer Therapeutics Market by Cancer Type, Drug Class, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Non-small cell lung cancer (NSCLC) Patient Pool Analysis, Market Size and Market Forecast APAC - 2034 - Product Image

Non-small cell lung cancer (NSCLC) Patient Pool Analysis, Market Size and Market Forecast APAC - 2034

  • Report
  • 120 Pages
  • Asia Pacific
From

About the Lung Cancer Drugs Market

The Lung Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat lung cancer. These drugs are used to treat both non-small cell and small cell lung cancer, the two most common types of lung cancer. The drugs are designed to target the cancer cells and stop them from growing and spreading. Common treatments include chemotherapy, targeted therapy, immunotherapy, and radiation therapy. The Lung Cancer Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Companies such as Bristol-Myers Squibb, Merck, Pfizer, AstraZeneca, and Roche are all major players in the market. These companies are constantly researching and developing new drugs to treat lung cancer, as well as improving existing treatments. In addition, there are many smaller companies that specialize in the development of new drugs for the treatment of lung cancer. These companies often collaborate with larger pharmaceutical companies to bring their drugs to market. Examples of these companies include ImmunoGen, Inc., Oncolytics Biotech, and ImmunoCellular Therapeutics. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.